Navigation Links
Human Extracellular Matrix Significantly Improves Device Biocompatibility
Date:5/28/2010

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present findings today at the American Society for Artificial Internal Organs (ASAIO) Annual Conference. Assessment of bioengineered, human extracellular matrix (hECM)-coated polymers showed a statistically significant reduction in immune cell infiltration, foreign body giant cell formation (pÂ0.05) and fibrous capsule formation (pÂ0.001), in addition to improved cell binding and proliferation, representing the potential for this hECM to significantly enhance the biocompatibility of various medical devices.

San Diego, CA (PRWEB) May 28, 2010 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present findings today at the American Society for Artificial Internal Organs (ASAIO) Annual Conference. Assessment of bioengineered, human extracellular matrix (hECM)-coated polymers showed a statistically significant reduction in immune cell infiltration, foreign body giant cell formation (p<0.05) and fibrous capsule formation (p<0.001), in addition to improved cell binding and proliferation, representing the potential for this hECM to significantly enhance the biocompatibility of various medical devices.

A large number of biomechanically suitable polymers, such as those devices utilized for cardiovascular, urological and hernia repair, fail due to the inflammatory and thrombogenic response by the body. Pre-clinical research on the insoluble, embryonic-like hECM produced through Histogen's unique manufacturing process has shown the capability of the material to significantly reduce these negative responses, and improve the performance of medical devices.

"Device implants represent an important and expanding multi-billion dollar market and have had a major impact on patient care," said Dr. Gail Naughton, CEO and Chairman of the Board at Histogen. "Problems such as fibrous capsule formation, poor tissue ingrowth, and neointimal hyperplasia resulting from suboptimal biocompatibility must be addressed to offer improved patient benefits. We are encouraged by the results with our embryonic-like matrix, which demonstrate its potential for reducing the foreign body reaction, as well as improving and prolonging the life and function of implantable devices."

Testing, which was performed as part of a partnership with the National Research Council's Advanced Materials Division, involved coating of several commonly utilized device materials, including nylon, polypropylene (PPE), and polyethylene terephthalate (PET) nonwoven scaffolds with hECM using several common coating methods. The hECM-coated and uncoated scaffolds were then surgically implanted in the subcutaneous space of SCID mice and histological samples of excised implants were assessed for inflammatory response, cellular infiltration, foreign body giant cells and capsule formation.

"Coating polymers with a naturally-produced, all-human ECM masks the foreign device material and offers a physiological surface which supports healthy tissue infiltration and interaction," said Dr. Michael Zimber, Director of Applied Research at Histogen. "The hECM-coated polymers promoted a two-fold increase in normal cell proliferation as compared to uncoated polymers, as well as causing a significant reduction in the host inflammatory and fibrotic response to surgically implanted polymers."

"Coating Polymers with a Human Extracellular Matrix Significantly Improves Implant Biocompatibility" will be presented by Dr. Zimber at the ASAIO Annual Conference, taking place May 27-29, 2010 in Baltimore.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit http://www.histogen.com.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4062814.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study finds law-like patterns in human preference behavior
2. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
3. Discovery of Stem Cell Illuminates Human Brain Evolution, Points To Therapies
4. The Human Spirit is Indomitable
5. Scientists Map Genetic Codes of Human Microbes
6. Oncolytic viruses mediating anti-tumor immunity in human cancer patients
7. BHM Healthcare Congratulates PORT Human Services: First to Receive CABHA Status
8. The cost of medicalizing human conditions
9. It was brawn over beauty in human mating competition
10. Human Touch Brand Ambassador and PGA Pro Tim Clark Wins First PGA TOUR Victory at PLAYERS Championship
11. McGill-UBC project creates mouse grimace scale to help identify pain in humans and animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... and related services to families and business owners in and around Lackawanna County, ... benefit senior citizens in the area. , Meals on Wheels of NEPA provides ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been partnering with ... grant funding to support its programs focused on providing opportunity to low-income families and ... grant by the Foundation of $15,000 to support its , Climb to College & ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians are unfamiliar ... integrate basic science with clinical practice. Now, however, a timely review has been published ... insight into the etiology of NeuP and educating preclinical scientists on its diagnosis and ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... announced today that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 ... expansion plans for some time, and Claritas Capital offers the smart money, speed ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, ... published a new eBook titled “ 5 Questions to Ask Before Entering the ... on the Genetic Test Evaluation (GTE) team, the book explores the various types ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... Calif. , June 14, 2017 The ... the City of Fremont and ... of the bio-pharma industry in California ... technology, enabling executive networking, and fostering workforce development. The ... development and growth of start-ups, as well as small ...
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology: